GlassScriptPhysician profile
Whitney W Moore
NPI 1164689071
$7,635.25
in general payments reported to CMS, 2019-2025
32 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,570 · 2022: $1,462 · 2023: $1,304 · 2024: $1,682 · 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,603.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.01 | 2021-2025 | |
| Novo Nordisk INC | $989.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $748.86 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $718.10 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $639.46 | 2021-2025 | |
| Amgen INC. | $469.80 | 2021-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $372.16 | 2021-2025 | Trintellix, Glassia |
| Abbott Laboratories | $255.17 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.40 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $203.95 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $183.20 | 2022-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $137.54 | 2021-2022 | |
| Axsome Therapeutics, INC. | $133.48 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $128.06 | 2021-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $120.02 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Medtronic, INC. | $116.60 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $102.23 | 2022 | |
| Exact Sciences Corporation | $91.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $87.50 | 2022-2024 | Quviviq |
| Esperion Therapeutics, INC. | $79.56 | 2022-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $68.43 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.68 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $40.34 | 2021 | |
| Collegium Pharmaceutical, INC. | $29.13 | 2021 | |
| Jazz Pharmaceuticals INC. | $26.71 | 2022 | |
| Ibsa Pharma INC. | $24.13 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.56 | 2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $15.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.79 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.78 | 2021 | |
| Apria Healthcare LLC | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.